<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Res Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">J Res Med Sci</journal-id><journal-id journal-id-type="publisher-id">JRMS</journal-id><journal-title-group><journal-title>Journal of Research in Medical Sciences : The Official Journal of Isfahan University of Medical Sciences</journal-title></journal-title-group><issn pub-type="ppub">1735-1995</issn><issn pub-type="epub">1735-7136</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25197295</article-id><article-id pub-id-type="pmc">4155708</article-id><article-id pub-id-type="publisher-id">JRMS-19-531</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Effects of probiotic yogurt consumption on lipid profile in type 2 diabetic patients: A randomized controlled clinical trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mohamadshahi</surname><given-names>Majid</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Veissi</surname><given-names>Masoud</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib><contrib contrib-type="author"><name><surname>Haidari</surname><given-names>Fatemeh</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib><contrib contrib-type="author"><name><surname>Javid</surname><given-names>Ahmad Zare</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib><contrib contrib-type="author"><name><surname>Mohammadi</surname><given-names>Fatemeh</given-names></name><xref ref-type="aff" rid="aff3">2</xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Shirbeigi</surname><given-names>Esmat</given-names></name><xref ref-type="aff" rid="aff4">3</xref></contrib></contrib-group><aff id="aff1">Hyperlipidemia Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran</aff><aff id="aff2"><label>1</label>Nutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran</aff><aff id="aff3"><label>2</label>Diabetes Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran</aff><aff id="aff4"><label>3</label>Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Fatemeh Mohammadi, Diabetes Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. E-mail: <email xlink:href="fatemehmohammadi58@gmail.com">fatemehmohammadi58@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>6</month><year>2014</year></pub-date><volume>19</volume><issue>6</issue><fpage>531</fpage><lpage>536</lpage><history><date date-type="received"><day>24</day><month>7</month><year>2013</year></date><date date-type="rev-recd"><day>05</day><month>9</month><year>2013</year></date><date date-type="accepted"><day>12</day><month>3</month><year>2014</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Journal of Research in Medical Sciences</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>Background:</title><p>Alteration in plasma lipid and lipoprotein profile has been documented in diabetic patients. The purpose of this study was to compare the effect of probiotic and conventional yogurt on lipid profile in type 2 diabetes mellitus patients.</p></sec><sec id="st2"><title>Materials and Methods:</title><p>A total of 44 patients with type 2 diabetes aged 30-60 years old who had low density lipoprotein cholesterol (LDL-c) &#x02265;100 mg/dl enrolled in this randomized, double &#x02013; blind controlled trial and were assigned to two intervention and control groups. The subjects in the intervention group consumed 300 g/d probiotic yogurt containing <italic>Lactobacillus acidophilus</italic> La-5 and <italic>Bifidobacterium lactis</italic> Bb-12 and subjects in the control group consumed 300 g/d conventional yogurt for 8 weeks. Anthropometric indices, dietary intake, and serum lipid profile were evaluated at the beginning and end of the intervention. Independent-sample <italic>t</italic>-test, paired sample <italic>t</italic>-test, ANCOVA, and repeated measures were used for statistical analysis.</p></sec><sec id="st3"><title>Results:</title><p>The consumption of probiotic yogurt caused significant decrease in LDL-c/high density lipoprotein cholesterol (HDL-c) ratio (3.13 &#x000b1; 1.00-2.07 &#x000b1; 0.71, <italic>P</italic> = 0.016). The levels of HDL-c were increased significantly (43.66 &#x000b1; 6.80-50.42 &#x000b1; 6.64, <italic>P</italic> = 0.023) in the intervention group postintervention. However, there were no significant differences in triglyceride and total cholesterol levels between two groups postintervention (<italic>P</italic> &#x0003c; 0.05).</p></sec><sec id="st4"><title>Conclusion:</title><p>It is suggested that probiotic yogurt consumption may be used as an alternative prevention approach and treatment method to improve dyslipidemia in patients with type 2 diabetes.</p></sec></abstract><kwd-group><kwd>Lipid profile</kwd><kwd>probiotic yogurt</kwd><kwd>type 2 diabetes</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>INTRODUCTION</title><p>Diabetes mellitus is one of the main endocrine diseases, which is more prevalent in the worldwide.[<xref rid="ref1" ref-type="bibr">1</xref>] Cardio-vascular disease, as one of several chronic disorders, is the major complication of type 2 diabetes mellitus (T2DM). Cardio-vascular disease may result from associated abnormalities of plasma lipid and lipoprotein metabolism.[<xref rid="ref2" ref-type="bibr">2</xref>] Alteration in plasma lipid and lipoprotein profile has been documented in diabetic patients.[<xref rid="ref3" ref-type="bibr">3</xref>] There are some reports in literature suggesting that the insulin resistance has a central role in the development of dyslipidemia in diabetic patients.[<xref rid="ref4" ref-type="bibr">4</xref><xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref6" ref-type="bibr">6</xref>] In insulin resistance status, free fatty acids flux from adipose tissue to liver and subsequently increase synthesis of very low density lipoprotein cholesterol and low density lipoprotein cholesterol (LDL-c) and decrease high density lipoprotein cholesterol (HDL-c) levels.[<xref rid="ref7" ref-type="bibr">7</xref>] Moreover, hyperglycemia in insulin resistance can lead to increase of advanced glycation end products density. These products may directly promote atherosclerosis through changes in endothelial, macrophage, and smooth muscle cells functions. Therefore, improving dyslipidemia would be effective to prevent complications of diabetic patients.[<xref rid="ref8" ref-type="bibr">8</xref>] Several treatments including consumption of herbal medicines,[<xref rid="ref9" ref-type="bibr">9</xref>] soy protein,[<xref rid="ref10" ref-type="bibr">10</xref>] w-3 fatty acids,[<xref rid="ref11" ref-type="bibr">11</xref>] and fiber[<xref rid="ref12" ref-type="bibr">12</xref>] have been suggested to improve dyslipidemia in diabetic patients. It is suggested that consumption of probiotics would be a novel approach to reduce the elevated levels of cholesterol.[<xref rid="ref13" ref-type="bibr">13</xref>] Probiotics are defined as live microorganisms which have beneficial health effects on their host, when enter the intestine with an adequate amount.[<xref rid="ref14" ref-type="bibr">14</xref>] Some of these health effects include: lowering hypercholesterolemia,[<xref rid="ref15" ref-type="bibr">15</xref>] prevention or management of diarrhea, constipation, lactose intolerance, diabetes mellitus,[<xref rid="ref16" ref-type="bibr">16</xref>] and colon cancer[<xref rid="ref17" ref-type="bibr">17</xref>] Two main groups of probiotic bacteria, which are most commonly used, involve <italic>Lactobacilli</italic> and <italic>Bifidobacteria</italic>.[<xref rid="ref18" ref-type="bibr">18</xref>] Some studies indicated that probiotics may be able to prevent increased levels of total cholesterol (TC), LDL-c and balance the ratio of LDL-c/HDL-c by de-conjugating of bile, hydrolysis of bile salts and increase cholesterol absorption, which consequently prevent and reduce the prevalence of cardio-vascular disease.[<xref rid="ref19" ref-type="bibr">19</xref>] Consumption of probiotics in healthy men increased in serum levels of HDL-c and reduced in LDL-c/HDL-c indices.[<xref rid="ref20" ref-type="bibr">20</xref>] Decreased serum LDL-c levels have been reported in hyper-lipidemic subjects by probiotic.[<xref rid="ref21" ref-type="bibr">21</xref>] Nevertheless, intake of <italic>Lactobacillus rhamnosus</italic> and <italic>Propionibacterium freudenreichii</italic> in hypercholesterolemia volunteers had no affect on lipid profile.[<xref rid="ref22" ref-type="bibr">22</xref>] As was mentioned, available evidences about the effects of probiotic bacteria on lipid profile are controversial.[<xref rid="ref20" ref-type="bibr">20</xref><xref rid="ref21" ref-type="bibr">21</xref><xref rid="ref22" ref-type="bibr">22</xref>] Therefore, this study with different type of probiotic bacteria was designed to evaluate the hypocholestrolemic effect of probiotic yogurt on lipid profile in patients with type 2 diabetes.</p></sec><sec sec-type="materials|methods" id="sec1-2"><title>MATERIALS AND METHODS</title><sec id="sec2-1"><title>Subjects</title><p>This study was conducted in 44 patients with T2DM were participated in this double-blind, randomized controlled clinical trial. This 8 weeks clinical trial was conducted from December 2011 to February 2012. The inclusion criteria included males and females, body mass index (BMI) &#x0003e;25, serum LDL-c level of &#x02265;100 mg/dl (normal range for men and women &#x0003c;100 mg/dl). Exclusion criteria included: insulin injection; any changes in using medication; smoking; lactose intolerance; thyroid dysfunction; chronic inflammatory diseases; cardio-vascular disease; renal dysfunction; pregnancy; breast feeding; and having any weight loose or weight gain regimes. The sample size was determined based on the primary information obtained from the study by Oze <italic>et al</italic>. for LDL-c.[<xref rid="ref20" ref-type="bibr">20</xref>] For an &#x003b1; value equal to 0.05 and a power of 80%, the sample size was computed as 15 per group. This number was increased to 22 per group to accommodate the anticipated dropout rate. The study was approved by the Research Ethic Committee of Ahvaz Jundishapur University of Medical Sciences, Iran (NRC - 9008). A written consent was obtained from all subjects.</p><p>All subjects were allocated into two groups using blocked randomization. For the subjects in the intervention group 300 g probiotic yogurt containing 3.7 &#x000d7; 10<sup>6</sup> cfu/mg of both <italic>Lactobacillus acidophilus</italic> La-5 and <italic>Bifidobacterium lactis</italic> Bb-12 (Chr. Hansen, Hoersholm, Denmark) was provided to consume every day for 8 weeks. On the other hand, the control group received 300 g/d conventional yogurt containing <italic>Lactobacillus bulgaricus</italic> and <italic>Streptococcus thermophiles</italic> for 8 weeks. The mean of the components of probiotic and conventional yogurt per 100 g is presented in <xref ref-type="table" rid="T1">Table 1</xref>. Both types of yogurts had a similar taste, appearance and specially prepared for this study by Pegah Dairy Industries Co. (Ahvaz, Iran). The patients were instructed to eat yogurt twice a day by lunch and dinner.[<xref rid="ref23" ref-type="bibr">23</xref>]</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Components of probiotic and conventional yogurt*</p></caption><graphic xlink:href="JRMS-19-531-g001"/></table-wrap><p>All subjects were asked to maintain their normal lifestyle, physical activity and eating habits and avoid consuming other probiotic and fermented products during the study. They also were asked to keep yogurts in the refrigerator at a temperature of below 4&#x000b0;C. Yogurts were freshly produced and provided to subjects weekly. The compliance with the yogurt consumption of all subjects was assessed twice a week by telephone interviews.</p><p>Anthropometric indices, dietary intakes and biochemical indices were evaluated in all subjects before and after intervention. Physical activity level was also evaluated and classified into low, moderate and vigorous levels.[<xref rid="ref24" ref-type="bibr">24</xref>] In this study, dietary intake of subjects was assessed by 3-day diet records and Nutritionist IV program was used to estimate dietary intake of patients. The body fat mass of subjects were also measured by body state set (QuadScan 4000).</p><p>A volume of 10 ml blood sample was collected and sera were separated, processed and stored at &#x02212;80 &#x000b0;C until analysis. Serum TC, triglycerides (TG) and HDL-c were measured enzymatically with Parsazmun's kits (DiaSys, Germany). LDL-c level was measured by Friedewald formula as follow:</p><p>LDL-c = TC &#x02013; HDL-c &#x02212; (triglyceride/5).</p></sec><sec id="sec2-2"><title>Statistical analyses</title><p>Statistical analyses were carried out using the Statistical Package for Social Sciences (SPSS Inc., Chicago, IL, USA) Program version 17 for windows. All data were expressed as mean &#x000b1; standard deviation Independent-sample <italic>t</italic>-test, paired sample <italic>t</italic>-test, ANCOVA and repeated measures were used for statistical analysis. <italic>P</italic> &#x0003c; 0.05 were considered to be significant.</p></sec></sec><sec id="sec1-3"><title>RESULT</title><p>In the current study, 42 patients attended randomization and blood collection. Thus, 21 subjects were randomly assigned to each group. Patients did not report any adverse effect during the study related to yogurt consumption and both yogurts were well-tolerated.</p><p>The mean age of subjects was 51 years. 26.19% (11 patients) of the study population was male and 73.80% (31 patients) was female. Regarding with the classification of physical activity level, 54.76%, 42.85, and 2.38% of the study population had low, moderate and vigorous physical activity level, respectively. However, there were not significant differences between two groups regarding with physical activity (<italic>P</italic> &#x0003e; 0.05).</p><p>Anthropometric characteristics of subjects at baseline and postintervention were shown in <xref ref-type="table" rid="T2">Table 2</xref>. For anthropometric parameters, no significant differences were seen between intervention and control groups at baseline and postintervention (<italic>P</italic> &#x0003e; 0.05).</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Anthropometric characteristics of subjects at baseline and postintervention</p></caption><graphic xlink:href="JRMS-19-531-g002"/></table-wrap><p>Regarding with dietary intake analysis, the differences in mean energy and nutrient intake were not significant (<italic>P</italic> &#x0003e; 0.05) between two groups at baseline. Calcium intake was increased in both groups after conventional and probiotic yogurt consumption, but not significantly (<italic>P</italic> = 0.061 and <italic>P</italic> = 0.057, respectively). Protein intake was significantly (<italic>P</italic> = 0.008) elevated in control group at the end of study. However, the intakes of other nutrients did not significantly change from baseline to the postintervention in both groups [<xref ref-type="table" rid="T3">Table 3</xref>].</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Dietary intakes of subjects at baseline and postintervention</p></caption><graphic xlink:href="JRMS-19-531-g003"/></table-wrap><p>In this study, the levels of HbA1c were significantly reduced in the intervention group compared with the control group at the end of study (7.09 &#x000b1; 1.23 vs. 8.09 &#x000b1; 1.58, <italic>P</italic> = 0.038). After adjusting for confounding factors (age, gender, physical activity, waist to hip ratio, and energy intake), the effects of probiotic and conventional yogurt consumption on lipid profile in patients with T2DM have been shown in <xref ref-type="table" rid="T4">Table 4</xref>. There were no significant differences found between two groups regarding with serum TC, TG, HDL-c and LDL-c at baseline. Serum levels of LDL-c were decreased in subjects in the intervention group post probiotic consumption, but not significantly (<italic>P</italic> = 0.059). Moreover, the LDL-c/HDL-c ratio was significantly reduced in the intervention group compared with the control group at the end of study. HDL-c levels were also significantly higher in the intervention group than in the control group postintervention (<italic>P</italic> = 0.023). However, no significant differences were observed in TC and TG levels between two groups at the end of study (<italic>P</italic> = 0.104 and <italic>P</italic> = 0.108 respectively). In the intervention group the levels of TC were significantly lowered postintervention (<italic>P</italic> = 0.044). Serum levels of TG were also diminished in the intervention group, but not significantly (<italic>P</italic> = 0.18).</p><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Effect of probiotic and conventional yogurt on lipid profile in the subjects</p></caption><graphic xlink:href="JRMS-19-531-g004"/></table-wrap></sec><sec sec-type="discussion" id="sec1-4"><title>DISCUSSION</title><p>Diabetes mellitus is an endocrine disorder that characterized by hyperglycemia[<xref rid="ref25" ref-type="bibr">25</xref>] and associated with disorders in lipid metabolism.[<xref rid="ref26" ref-type="bibr">26</xref>] Dyslipidemia is a major risk factor for cardio-vascular disease in patients with diabetes.[<xref rid="ref27" ref-type="bibr">27</xref>] Some human and animal studies suggested that using probiotic may reduce serum lipid levels.[<xref rid="ref28" ref-type="bibr">28</xref><xref rid="ref29" ref-type="bibr">29</xref>] Therefore, this study was carried out to evaluate probiotic effects on lipid profile in patients with T2DM. In the present study, none of the subjects reported any adverse effect during the study related to yogurt consumption and it was reported that both kinds of yogurts were well-tolerated, therefore it is suggested that the compliance rate was satisfied. There were no significant differences observed in dietary intake, anthropometric indices and physical activity level between probiotic and conventional consumers during the study. Hence, it is suggested that these possible confounders did not affect on the results of lipid profiles in this study. In another study, Sadrzadeh-Yeganeh <italic>et al</italic>. indicated that use of <italic>L. acidophilus</italic> La-5 and <italic>B. lactis</italic> Bb-12 didn&#x02019;t significant changes anthropometry indices in hypercholestrolemic patients.[<xref rid="ref30" ref-type="bibr">30</xref>] Results of the study by Fuentes <italic>et al</italic>. also indicated that 12 weeks consumption of <italic>Lactobacillus plantarum</italic> has no effect on weight, BMI, body fat mass in hyper-cholesterolemic subjects.[<xref rid="ref31" ref-type="bibr">31</xref>] In other experiments shown that body weight and weight of liver were not affected by B. lactis Bb-12 in wild type mice.[<xref rid="ref32" ref-type="bibr">32</xref>]</p><p>In this study, it was shown that consumption of probiotic yogurt significantly reduced HbA1c levels. The results also showed that consumption of probiotic yogurt significantly reduced serum levels of LDL-c and LDL-c/HDL-c ratio, in patients with T2DM patients. Moreover, serum HDL-c levels were significantly increased after consumption of probiotic yogurt. These results concur with other studies. Ejtahed <italic>et al</italic>. found that consumption of probiotic yogurt in T2DM patients significantly reduced HbA1c concentration and serum levels of LDL-c and LDL-c/HDL-c ratio.[<xref rid="ref33" ref-type="bibr">33</xref>] Decreased serum levels of LDL-c by <italic>Lactobacillus reuteri</italic> NCIBM30242 have been also reported by Jones <italic>et al</italic>.[<xref rid="ref34" ref-type="bibr">34</xref>] In a study by Wang <italic>et al</italic>., it was indicated that <italic>Lactobacillus</italic> LIP-1 and MG9-2 significantly decreased serum level of TG, TC and LDL-c in high-lipid diet fed mice.[<xref rid="ref35" ref-type="bibr">35</xref>] Baroutkoub <italic>et al</italic>. found that <italic>L. acidophilus</italic> and <italic>B. lactis</italic> significantly reduced LDL-c and TC level in hypercholestrolemic patients.[<xref rid="ref19" ref-type="bibr">19</xref>] Consumption of a new symbiotic shake containing <italic>L. acidophilus</italic>, <italic>B. bifidum</italic> and fructo-oligosaccharides in older with type 2 diabetic patients significantly increased serum HDL-c, but did not impact on TC and TG in Moroti <italic>et al</italic>. Study.[<xref rid="ref36" ref-type="bibr">36</xref>] Improvement of LDL-c/HDL-c ratio and increased serum level of HDL-c by probiotic have been reported in Kiessling <italic>et al</italic>. trial.[<xref rid="ref37" ref-type="bibr">37</xref>] In another study, Fabian and Elmadfa found that daily consumption of probiotic yogurt significantly raised serum HDL-c and improved ratio of LDL-c/HDL-c.[<xref rid="ref38" ref-type="bibr">38</xref>]</p><p>However, there are some other studies in contrast with our study regarding with the above-mentioned results. Asemi <italic>et al</italic>. showed that eating probiotic yogurt did not change lipid profile in pregnant women.[<xref rid="ref39" ref-type="bibr">39</xref>] Sadrzadeh-Yeganeh <italic>et al</italic>. also reported similar results in women.[<xref rid="ref29" ref-type="bibr">29</xref>] Moreover, Hattaka <italic>et al</italic>. indicated that intake of <italic>L. rhamnosus</italic> LC705 did not affect blood lipids in hyperlipidemic men.[<xref rid="ref22" ref-type="bibr">22</xref>]</p><p>There are several possible mechanisms suggested about the effects of probiotic bacteria on lipid profile. It is indicated that different bacteria species may have different abilities to affect lipid profile.[<xref rid="ref29" ref-type="bibr">29</xref><xref rid="ref40" ref-type="bibr">40</xref>]</p><p>Lee do <italic>et al</italic>. showed that short chain fatty acids that are produced by lactic acid bacteria could inhibit the enzymatic synthesis of cholesterol.[<xref rid="ref40" ref-type="bibr">40</xref>] Probiotic bacteria may also facilitate excreting of cholesterol through feces.[<xref rid="ref36" ref-type="bibr">36</xref>] Furthermore, these bacteria can assimilate cholesterol and lead to its reduction. Moreover, it is suggested that lactic acid bacteria may bind with cholesterol and inhibit its reabsorption in the body.[<xref rid="ref41" ref-type="bibr">41</xref>] In addition, <italic>Lactobacilli</italic> and <italic>Bifidobacteria</italic> cells are able to hydrolyze conjugated bile acids, excrete them faster and reduce its level to which they can be absorbed.[<xref rid="ref42" ref-type="bibr">42</xref><xref rid="ref43" ref-type="bibr">43</xref>] The findings of this study also suggested that probiotic yogurt consumption might not affect on serum TC and TG levels in patients with T2DM due to some possibilities that we suggest the type of microorganism used and some limitations of study including the number of subjects and short period of intervention in this study.</p></sec><sec sec-type="conclusion" id="sec1-5"><title>CONCLUSION</title><p>This study indicated that consuming probiotic yogurt can improve lipid abnormalities in patients with T2DM. Therefore, it is suggested that eating probiotic yogurt may be used as an alternative prevention approach and treatment method to reduce diabetic complications. We also suggest further studies with larger sample size, longer period of intervention and various type of probiotic.</p></sec></body><back><ack><title>ACKNOWLEDGMENT</title><p>This paper is issued from the MSc thesis of Fatemeh Mohammadi, and the financial support was provided by Nutrition and Metabolic Diseases Research Center and Student Research Committee, Ahvaz Jundishapur University of Medical Sciences (Grant number NRC-9008). This trial was registered in Iranian Registry of Clinical Trials with ID number of IRCT2014021516588N1.</p></ack><fn-group><fn fn-type="supported-by"><p><bold>Source of Support:</bold> Financial support was provided by Nutrition and Metabolic Diseases Research Center and Student Research Committee, Ahvaz Jundishapur University of Medical Sciences</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> None declared.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heydari</surname><given-names>I</given-names></name><name><surname>Radi</surname><given-names>V</given-names></name><name><surname>Razmjou</surname><given-names>S</given-names></name><name><surname>Amiri</surname><given-names>A</given-names></name></person-group><article-title>Chronic complications of diabetes mellitus in newly diagnosed patients</article-title><source>Int J Diabetes Mellit</source><year>2010</year><volume>2</volume><fpage>61</fpage><lpage>63</lpage></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunn</surname><given-names>FL</given-names></name></person-group><article-title>Management of dyslipidemia in people with type 2 diabetes mellitus</article-title><source>Rev Endocr Metab Disord</source><year>2010</year><volume>11</volume><fpage>41</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">20221703</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shafrir</surname><given-names>E</given-names></name><name><surname>Raz</surname><given-names>I</given-names></name></person-group><article-title>Diabetes: Mellitus or lipidus?</article-title><source>Diabetologia</source><year>2003</year><volume>46</volume><fpage>433</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">12687345</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krauss</surname><given-names>RM</given-names></name><name><surname>Siri</surname><given-names>PW</given-names></name></person-group><article-title>Dyslipidemia in type 2 diabetes</article-title><source>Med Clin North Am</source><year>2004</year><volume>88</volume><fpage>897</fpage><lpage>909</lpage><comment>x</comment><pub-id pub-id-type="pmid">15308384</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Del Pilar</surname><given-names>Solano M</given-names></name><name><surname>Goldberg</surname><given-names>RB</given-names></name></person-group><article-title>Management of diabetic dyslipidemia</article-title><source>Endocrinol Metab Clin North Am</source><year>2005</year><volume>34</volume><fpage>1</fpage><lpage>25</lpage><comment>v</comment><pub-id pub-id-type="pmid">15752919</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chahil</surname><given-names>TJ</given-names></name><name><surname>Ginsberg</surname><given-names>HN</given-names></name></person-group><article-title>Diabetic dyslipidemia</article-title><source>Endocrinol Metab Clin North Am</source><year>2006</year><volume>35</volume><fpage>491</fpage><pub-id pub-id-type="pmid">16959582</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mooradian</surname><given-names>AD</given-names></name></person-group><article-title>Dyslipidemia in type 2 diabetes mellitus</article-title><source>Nat Clin Pract Endocrinol Metab</source><year>2009</year><volume>5</volume><fpage>150</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">19229235</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rader</surname><given-names>DJ</given-names></name></person-group><article-title>Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus</article-title><source>Am J Med</source><year>2007</year><volume>120</volume><fpage>S12</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">17320517</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houston</surname><given-names>MC</given-names></name><name><surname>Fazio</surname><given-names>S</given-names></name><name><surname>Chilton</surname><given-names>FH</given-names></name><name><surname>Wise</surname><given-names>DE</given-names></name><name><surname>Jones</surname><given-names>KB</given-names></name><name><surname>Barringer</surname><given-names>TA</given-names></name><etal/></person-group><article-title>Nonpharmacologic treatment of dyslipidemia</article-title><source>Prog Cardiovasc Dis</source><year>2009</year><volume>52</volume><fpage>61</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">19732602</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>R</given-names></name></person-group><article-title>Food and food supplements with hypocholesterolemic effects</article-title><source>Recent Pat Food Nutr Agric</source><year>2009</year><volume>1</volume><fpage>15</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">20653522</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McEwen</surname><given-names>B</given-names></name><name><surname>Morel-Kopp</surname><given-names>MC</given-names></name><name><surname>Tofler</surname><given-names>G</given-names></name><name><surname>Ward</surname><given-names>C</given-names></name></person-group><article-title>Effect of omega-3 fish oil on cardiovascular risk in diabetes</article-title><source>Diabetes Educ</source><year>2010</year><volume>36</volume><fpage>565</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">20534874</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaczmarczyk</surname><given-names>MM</given-names></name><name><surname>Miller</surname><given-names>MJ</given-names></name><name><surname>Freund</surname><given-names>GG</given-names></name></person-group><article-title>The health benefits of dietary fiber: Beyond the usual suspects of type 2 diabetes mellitus, cardiovascular disease and colon cancer</article-title><source>Metabolism</source><year>2012</year><volume>61</volume><fpage>1058</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">22401879</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavlovi&#x00107;</surname><given-names>N</given-names></name><name><surname>Stankov</surname><given-names>K</given-names></name><name><surname>Mikov</surname><given-names>M</given-names></name></person-group><article-title>Probiotics &#x02013; Interactions with bile acids and impact on cholesterol metabolism</article-title><source>Appl Biochem Biotechnol</source><year>2012</year><volume>168</volume><fpage>1880</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">23054820</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>da Costa</surname><given-names>Baptista IP</given-names></name><name><surname>Accioly</surname><given-names>E</given-names></name><name><surname>de Carvalho</surname><given-names>Padilha P</given-names></name></person-group><article-title>Effect of the use of probiotics in the treatment of children with atopic dermatitis; a literature review</article-title><source>Nutr Hosp</source><year>2013</year><volume>28</volume><fpage>16</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">23808426</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhuang</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Tian</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Research advances with regards to clinical outcome and potential mechanisms of the cholesterol-lowering effects of probiotics</article-title><source>Clin Lipidol</source><year>2012</year><volume>7</volume><fpage>501</fpage><lpage>7</lpage></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagpal</surname><given-names>R</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Kumar</surname><given-names>M</given-names></name><name><surname>Behare</surname><given-names>PV</given-names></name><name><surname>Jain</surname><given-names>S</given-names></name><name><surname>Yadav</surname><given-names>H</given-names></name></person-group><article-title>Probiotics, their health benefits and applications for developing healthier foods: A review</article-title><source>FEMS Microbiol Lett</source><year>2012</year><volume>334</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">22568660</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagaraj</surname><given-names>T</given-names></name><name><surname>Ravi</surname><given-names>B</given-names></name><name><surname>Sankaran</surname><given-names>SN</given-names></name><name><surname>Madhu</surname><given-names>K</given-names></name></person-group><article-title>Probiotics and oral health</article-title><source>J Indian Acad Oral Med Radiol</source><year>2012</year><volume>24</volume><fpage>146</fpage><lpage>8</lpage></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Upadhya</surname><given-names>N</given-names></name><name><surname>Moudga</surname><given-names>V</given-names></name></person-group><article-title>Probiotics: A review</article-title><source>J Sci Commun</source><year>2012</year><volume>19</volume><fpage>76</fpage><lpage>84</lpage></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baroutkoub</surname><given-names>A</given-names></name><name><surname>Zamir</surname><given-names>MR</given-names></name><name><surname>Razmik</surname><given-names>B</given-names></name><name><surname>Julayi</surname><given-names>H</given-names></name><name><surname>Sohrabi</surname><given-names>Z</given-names></name><name><surname>Mazloomi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effects of probiotic yoghurt consumption on the serum cholesterol levels in hypercholestromic cases in Shiraz, Southern Iran</article-title><source>Sci Res Essays</source><year>2010</year><volume>5</volume><fpage>2206</fpage><lpage>9</lpage></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oze</surname><given-names>GO</given-names></name><name><surname>Nwanjo</surname><given-names>HU</given-names></name><name><surname>Opara</surname><given-names>AU</given-names></name><name><surname>Ojiegbe</surname><given-names>GC</given-names></name><name><surname>Nwankpa</surname><given-names>P</given-names></name><name><surname>Ihim</surname><given-names>AC</given-names></name></person-group><article-title>Effect of Yoghurt (Milk Fermented by <italic>Lactobacillus acidophilus</italic>) on plasma lipid profiles and blood pressure levels in Nigerian males</article-title><source>Niger J Biochem Mol Biol</source><year>2008</year><volume>23</volume><fpage>30</fpage><lpage>4</lpage></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ataie-Jafari</surname><given-names>A</given-names></name><name><surname>Larijani</surname><given-names>B</given-names></name><name><surname>Alavi</surname><given-names>Majd H</given-names></name><name><surname>Tahbaz</surname><given-names>F</given-names></name></person-group><article-title>Cholesterol-lowering effect of probiotic yogurt in comparison with ordinary yogurt in mildly to moderately hypercholesterolemic subjects</article-title><source>Ann Nutr Metab</source><year>2009</year><volume>54</volume><fpage>22</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">19229114</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatakka</surname><given-names>K</given-names></name><name><surname>Mutanen</surname><given-names>M</given-names></name><name><surname>Holma</surname><given-names>R</given-names></name><name><surname>Saxelin</surname><given-names>M</given-names></name><name><surname>Korpela</surname><given-names>R</given-names></name></person-group><article-title><italic>Lactobacillus rhamnosus</italic> LC705 together with <italic>Propionibacterium freudenreichii</italic> ssp shermanii JS administered in capsules is ineffective in lowering serum lipids</article-title><source>J Am Coll Nutr</source><year>2008</year><volume>27</volume><fpage>441</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">18978162</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghadamli</surname><given-names>L</given-names></name><name><surname>Salarkia</surname><given-names>N</given-names></name><name><surname>Zayeri</surname><given-names>F</given-names></name><name><surname>Rad</surname><given-names>LS</given-names></name></person-group><article-title>Effects of probiotic yogurt on performance, respiratory infections, and digestive disorders of endurance young adult women-swimmers</article-title><source>Iran J Nutr Sci Food Technol</source><year>2010</year><volume>5</volume><fpage>9</fpage><lpage>18</lpage></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="book"><article-title>US Department of Health and Human Services. Physical Activity Guidelines for Americans</article-title><year>2008</year><publisher-loc>Washington DC</publisher-loc><publisher-name>USDHHS</publisher-name><fpage>21</fpage><lpage>5</lpage></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seino</surname><given-names>Y</given-names></name><name><surname>Nanjo</surname><given-names>K</given-names></name><name><surname>Tajima</surname><given-names>N</given-names></name><name><surname>Araki</surname><given-names>E</given-names></name><name><surname>Ito</surname><given-names>C</given-names></name><name><surname>Inagaki</surname><given-names>N</given-names></name><etal/></person-group><article-title>Report of the committee on the classification and diagnostic criteria of diabetes mellitus</article-title><source>J Diabetes Investig</source><year>2010</year><volume>1</volume><fpage>212</fpage><lpage>28</lpage></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toth</surname><given-names>PP</given-names></name><name><surname>Zarotsky</surname><given-names>V</given-names></name><name><surname>Sullivan</surname><given-names>JM</given-names></name><name><surname>Laitinen</surname><given-names>D</given-names></name></person-group><article-title>Dyslipidemia treatment of patients with diabetes mellitus in a US managed care plan: A retrospective database analysis</article-title><source>Cardiovasc Diabetol</source><year>2009</year><volume>8</volume><fpage>26</fpage><pub-id pub-id-type="pmid">19450274</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ginsberg</surname><given-names>HN</given-names></name><name><surname>MacCallum</surname><given-names>PR</given-names></name></person-group><article-title>The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus</article-title><source>J Cardiometab Syndr</source><year>2009</year><volume>4</volume><fpage>113</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">19614799</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhathena</surname><given-names>J</given-names></name><name><surname>Martoni</surname><given-names>C</given-names></name><name><surname>Kulamarva</surname><given-names>A</given-names></name><name><surname>Urbanska</surname><given-names>AM</given-names></name><name><surname>Malhotra</surname><given-names>M</given-names></name><name><surname>Prakash</surname><given-names>S</given-names></name></person-group><article-title>Orally delivered microencapsulated live probiotic formulation lowers serum lipids in hypercholesterolemic hamsters</article-title><source>J Med Food</source><year>2009</year><volume>12</volume><fpage>310</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">19459731</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>AC</given-names></name><name><surname>Valiere</surname><given-names>A</given-names></name></person-group><article-title>Probiotics and medical nutrition therapy</article-title><source>Nutr Clin Care</source><year>2004</year><volume>7</volume><fpage>56</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">15481739</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadrzadeh-Yeganeh</surname><given-names>H</given-names></name><name><surname>Elmadfa</surname><given-names>I</given-names></name><name><surname>Djazayery</surname><given-names>A</given-names></name><name><surname>Jalali</surname><given-names>M</given-names></name><name><surname>Heshmat</surname><given-names>R</given-names></name><name><surname>Chamary</surname><given-names>M</given-names></name></person-group><article-title>The effects of probiotic and conventional yoghurt on lipid profile in women</article-title><source>Br J Nutr</source><year>2010</year><volume>103</volume><fpage>1778</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">20100374</pub-id></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuentes</surname><given-names>MC</given-names></name><name><surname>Lajo</surname><given-names>T</given-names></name><name><surname>Carri&#x000f3;n</surname><given-names>JM</given-names></name><name><surname>Cu&#x000f1;&#x000e9;</surname><given-names>J</given-names></name></person-group><article-title>Cholesterol-lowering efficacy of <italic>Lactobacillus plantarum</italic> CECT 7527, 7528 and 7529 in hypercholesterolaemic adults</article-title><source>Br J Nutr</source><year>2013</year><volume>109</volume><fpage>1866</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">23017585</pub-id></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuo</surname><given-names>SM</given-names></name><name><surname>Merhige</surname><given-names>PM</given-names></name><name><surname>Hagey</surname><given-names>LR</given-names></name></person-group><article-title>The effect of dietary prebiotics and probiotics on body weight, large intestine indices, and fecal bile acid profile in wild type and IL10-/- mice</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e60270</fpage><pub-id pub-id-type="pmid">23555939</pub-id></element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ejtahed</surname><given-names>HS</given-names></name><name><surname>Mohtadi-Nia</surname><given-names>J</given-names></name><name><surname>Homayouni-Rad</surname><given-names>A</given-names></name><name><surname>Niafar</surname><given-names>M</given-names></name><name><surname>Asghari-Jafarabadi</surname><given-names>M</given-names></name><name><surname>Mofid</surname><given-names>V</given-names></name><etal/></person-group><article-title>Effect of probiotic yogurt containing <italic>Lactobacillus acidophilus</italic> and <italic>Bifidobacterium lactis</italic> on lipid profile in individuals with type 2 diabetes mellitus</article-title><source>J Dairy Sci</source><year>2011</year><volume>94</volume><fpage>3288</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">21700013</pub-id></element-citation></ref><ref id="ref34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>ML</given-names></name><name><surname>Martoni</surname><given-names>CJ</given-names></name><name><surname>Parent</surname><given-names>M</given-names></name><name><surname>Prakash</surname><given-names>S</given-names></name></person-group><article-title>Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active <italic>Lactobacillus reuteri</italic> NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults</article-title><source>Br J Nutr</source><year>2012</year><volume>107</volume><fpage>1505</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">22067612</pub-id></element-citation></ref><ref id="ref35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Menghebilige</surname></name><name><surname>Bao</surname><given-names>Q</given-names></name></person-group><article-title>Selection of potential probiotic lactobacilli for cholesterol-lowering properties and their effect on cholesterol metabolism in rats fed a high-lipid diet</article-title><source>J Dairy Sci</source><year>2012</year><volume>95</volume><fpage>1645</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">22459813</pub-id></element-citation></ref><ref id="ref36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moroti</surname><given-names>C</given-names></name><name><surname>Souza</surname><given-names>Magri LF</given-names></name><name><surname>de Rezende</surname><given-names>Costa M</given-names></name><name><surname>Cavallini</surname><given-names>DC</given-names></name><name><surname>Sivieri</surname><given-names>K</given-names></name></person-group><article-title>Effect of the consumption of a new symbiotic shake on glycemia and cholesterol levels in elderly people with type 2 diabetes mellitus</article-title><source>Lipids Health Dis</source><year>2012</year><volume>11</volume><fpage>29</fpage><pub-id pub-id-type="pmid">22356933</pub-id></element-citation></ref><ref id="ref37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiessling</surname><given-names>G</given-names></name><name><surname>Schneider</surname><given-names>J</given-names></name><name><surname>Jahreis</surname><given-names>G</given-names></name></person-group><article-title>Long-term consumption of fermented dairy products over 6 months increases HDL cholesterol</article-title><source>Eur J Clin Nutr</source><year>2002</year><volume>56</volume><fpage>843</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12209372</pub-id></element-citation></ref><ref id="ref38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fabian</surname><given-names>E</given-names></name><name><surname>Elmadfa</surname><given-names>I</given-names></name></person-group><article-title>Influence of daily consumption of probiotic and conventional yoghurt on the plasma lipid profile in young healthy women</article-title><source>Ann Nutr Metab</source><year>2006</year><volume>50</volume><fpage>387</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">16816529</pub-id></element-citation></ref><ref id="ref39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asemi</surname><given-names>Z</given-names></name><name><surname>Samimi</surname><given-names>M</given-names></name><name><surname>Tabasi</surname><given-names>Z</given-names></name><name><surname>Talebian</surname><given-names>P</given-names></name><name><surname>Azarbad</surname><given-names>Z</given-names></name><name><surname>Hydarzadeh</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Effect of daily consumption of probiotic yoghurt on lipid profiles in pregnant women: A randomized controlled clinical trial</article-title><source>J Matern Fetal Neonatal Med</source><year>2012</year><volume>25</volume><fpage>1552</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">22098090</pub-id></element-citation></ref><ref id="ref40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee do</surname><given-names>K</given-names></name><name><surname>Jang</surname><given-names>S</given-names></name><name><surname>Baek</surname><given-names>EH</given-names></name><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Lee</surname><given-names>KS</given-names></name><name><surname>Shin</surname><given-names>HS</given-names></name><etal/></person-group><article-title>Lactic acid bacteria affect serum cholesterol levels, harmful fecal enzyme activity, and fecal water content</article-title><source>Lipids Health Dis</source><year>2009</year><volume>8</volume><fpage>21</fpage><pub-id pub-id-type="pmid">19515264</pub-id></element-citation></ref><ref id="ref41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akbarzadeh</surname><given-names>F</given-names></name><name><surname>Homayouni</surname><given-names>A</given-names></name></person-group><article-title>Dairy Probiotic Foods and Coronary Heart Disease: A Review on Mechanism of Action</article-title><year>2012</year><issue>Ch. 5</issue><fpage>121</fpage><lpage>8</lpage><comment>InTech</comment></element-citation></ref><ref id="ref42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ooi</surname><given-names>LG</given-names></name><name><surname>Liong</surname><given-names>MT</given-names></name></person-group><article-title>Cholesterol-lowering effects of probiotics and prebiotics: A review of <italic>in vivo</italic> and <italic>in vitro</italic> findings</article-title><source>Int J Mol Sci</source><year>2010</year><volume>11</volume><fpage>2499</fpage><lpage>522</lpage><pub-id pub-id-type="pmid">20640165</pub-id></element-citation></ref><ref id="ref43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Begley</surname><given-names>M</given-names></name><name><surname>Hill</surname><given-names>C</given-names></name><name><surname>Gahan</surname><given-names>CG</given-names></name></person-group><article-title>Bile salt hydrolase activity in probiotics</article-title><source>Appl Environ Microbiol</source><year>2006</year><volume>72</volume><fpage>1729</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">16517616</pub-id></element-citation></ref></ref-list></back></article>